Dexcom (DXCM) Cash from Investing Activities (2010 - 2026)

Dexcom (DXCM) has reported Cash from Investing Activities for 17 consecutive years, with $329.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 618.55% year-over-year to $329.8 million in Q2 2026; TTM through Jun 2026 was $530.7 million, a 1034.33% increase from a year earlier, with the FY2025 full-year figure at $536.0 million, up 358.31% from the prior year.
• Cash from Investing Activities was $329.8 million for Q2 2026 at Dexcom, up from -$298.5 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $414.9 million in Q4 2023 and troughed at -$555.9 million in Q2 2023.
• A 5-year average of -$37.2 million and a median of -$104.2 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 690.69% in 2022 and slumped 397.9% in 2026, its largest moves.
• Over 5 years, Cash from Investing Activities stood at -$194.1 million in 2022, then jumped by 313.76% to $414.9 million in 2023, then plunged by 173.2% to -$303.7 million in 2024, then soared by 200.95% to $306.6 million in 2025, then gained by 7.57% to $329.8 million in 2026.
• The last three Cash from Investing Activities figures came in at $329.8 million (Q2 2026), -$298.5 million (Q1 2026), and $306.6 million (Q4 2025), per Business Quant data.